Aroxybutynin;Atomoxetine;atomoxetine hydrochloride
- Generic Name
- Aroxybutynin;Atomoxetine;atomoxetine hydrochloride
Study That Tests AD109 in Patients Taking GLP-1 Drugs
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Apnimed
- Target Recruit Count
- 40
- Registration Number
- NCT06400615
- Locations
- 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States
🇺🇸Monroe Biomedical Research, Monroe, North Carolina, United States
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Apnimed
- Target Recruit Count
- 646
- Registration Number
- NCT05813275
- Locations
- 🇺🇸
Noble Clinical Research, Tucson, Arizona, United States
🇺🇸The Heights Hospital (HD Heights), Houston, Texas, United States
🇺🇸JSV Clinical Research Study Inc, Tampa, Florida, United States
Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)
- First Posted Date
- 2023-04-13
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Apnimed
- Target Recruit Count
- 660
- Registration Number
- NCT05811247
- Locations
- 🇺🇸
Santa Monica Clinical Trials, Los Angeles, California, United States
🇺🇸Coastal Carolina Health Care, New Bern, North Carolina, United States
🇺🇸NeuroTrials Research, Atlanta, Georgia, United States
Parallel Arm Trial of AD109 and AD504 In Patients With OSA
- Conditions
- OSA - Obstructive Sleep Apnea
- Interventions
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Apnimed
- Target Recruit Count
- 294
- Registration Number
- NCT05071612
- Locations
- 🇺🇸
Velocity Clinical Research, Greenville, South Carolina, United States
🇺🇸The Center for Sleep & Wake Disorders, Chevy Chase, Maryland, United States
🇺🇸NeuroTrials Research, Inc., Atlanta, Georgia, United States
Crossover Trial of AD109 in Obstructive Sleep Apnea
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Drug: R-oxybutyninDrug: PlaceboDiagnostic Test: Digit System Substitution Test
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Apnimed
- Target Recruit Count
- 60
- Registration Number
- NCT04580394
- Locations
- 🇺🇸
Preferred Research Partners, Inc., Little Rock, Arkansas, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸Teradan Clinical Trials, Brandon, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.